Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma

Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma

Abstract Background Nivolumab is approved for patients with metastatic renal cell carcinoma (mRCC) refractory to prior antiangiogenic therapy. The clinical activity of nivolumab in patients with non-clear cell RCC subtypes remains unknown as these patients were excluded from the original nivolumab t...

Full description

Bibliographic Details
Main Authors: Vadim S. Koshkin, Pedro C. Barata, Tian Zhang, Daniel J. George, Michael B. Atkins, William J. Kelly, Nicholas J. Vogelzang, Sumanta K. Pal, JoAnn Hsu, Leonard J. Appleman, Moshe C. Ornstein, Timothy Gilligan, Petros Grivas, Jorge A. Garcia, Brian I. Rini
Format: Article
Language:English
Published: BMJ Publishing Group 2018-01-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Non-clear cell renal cell carcinoma
mRCC
Nivolumab
Immunotherapy
PD1/PDL1 pathway
Checkpoint inhibitor
Online Access:http://link.springer.com/article/10.1186/s40425-018-0319-9

Internet

http://link.springer.com/article/10.1186/s40425-018-0319-9

Similar Items